Clinical Core

临床核心综述 核心的总体目标将是为大型临床提供研究诊断评估 人口，特别强调参与者，他们被纵向跟踪并追踪到身体解剖 为ADRC调查人员开展的研究项目提供有特色的参与者 合作者。临床核心的重要关注点--就耶鲁大学ADRC而言--包括细胞 神经科学，突触机制，以及对生物样品的系统储存的重视 未来的生物标记物研究。神经影像和液体生物标记物在AD诊断和治疗中的重要性 治疗的发展越来越受到人们的重视，最近的研究强调了 根据β-淀粉样蛋白沉积的存在、病理性tau和 神经变性(ATN)。耶鲁大学ADRC影像、生物标记物和神经病理学核心和特异性 发展项目将寻求开发与阿尔茨海默病和相关疾病相关的这些方法。在……里面 在这些努力的伙伴关系下，临床核心将承担收集广泛的成像研究 和流体生物标记物标本横断面和在AD的全过程中 纵向的，纵向的目标1将通过招募250名新参与者来维持核心人口 AD的完整连续体(从临床前到痴呆)，以及非AD痴呆和正常对照组。目标2 将这些参与者登记到统一数据集(UDS)人群中，并使UDS测量可用 提交给国家阿尔茨海默氏症协调中心(NACC)进行国家研究。目标3将招收受试者参加 验尸程序。AIM 4将为ADRC附属的临床研究提供适当的对象。目标 5将为耶鲁大学ADRC和其他研究人员收集生物标本，用于生物标记物研究。AIM 6将提供协助 研究性教育在培养AD及相关领域未来临床和转化型研究人员中的核心作用 精神错乱。这些目标将为ADRC附属调查人员提供随时测试生物标记物的能力-一次 在AD痴呆中得到验证--在AD发病的最早阶段。

SUMMARY OF THE CLINICAL CORE The over-arching goal of the Core will be to provide research diagnostic evaluations for a large clinical population with a special emphasis on participants who are followed longitudinally and tracked to autopsy to provide well-characterized participants for the research projects conducted by ADRC investigators and collaborators. Important focuses of the Clinical Core—as for the Yale ADRC broadly—include cellular neuroscience, synaptic mechanisms, and an emphasis on systematic storage of biospecimens for current and future biomarker studies. The importance of neuroimaging and fluid biomarkers for AD diagnosis and therapeutic development is increasing well appreciated, and recent research has emphasized the importance of classifying patients according to the presence of β-amyloid deposition, pathologic tau, and neurodegeneration (ATN). The Yale ADRC Imaging, Biomarker, and Neuropathology Cores and specific Developmental Projects will seek to develop these methods with relevance to AD and related disorders. In partnership with these efforts, the Clinical Core will undertake the collection of a wide range of imaging studies and fluid biomarker specimens across the full spectrum of AD cross-sectionally and during the full course of AD longitudinally. Aim 1 will maintain the Core Population through enrollment of 250 new participants on the full continuum of AD (from preclinical to dementia), as well as non-AD dementias and normal controls. Aim 2 will enroll these participants in the Uniform Data Set (UDS) population and make the UDS measures available to the National Alzheimer’s Coordinating Center (NACC) for national studies. Aim 3 will enroll subjects into the Autopsy Program. Aim 4 will provide appropriate subjects for the clinical studies affiliated with the ADRC. Aim 5 will collect biological specimens for Yale ADRC and other researchers for biomarker studies. Aim 6 will assist the Research Education Core in training future clinical and translational researchers in AD and related disorders. These Aims will provide ADRC affiliated investigators the ready ability to test biomarkers—once validated in AD dementia—in the earliest stages of AD pathogenesis.